Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-Glycoprotein

11 Jul 2012

Abstract excerpt

The IGROVCDDP cisplatin-resistant ovarian cancer cell line is also resistant to paclitaxel and models the resistance phenotype of relapsed ovarian cancer patients after first-line platinum/taxane chemotherapy. A TaqMan low-density array (TLDA) was used to characterise the expression of 380 genes associated with chemotherapy resistance in IGROVCDDP cells. Paclitaxel resistance in IGROVCDDP is mediated by gene and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Transport and Resistance Mechanisms
Share to Pregnancy and Medication Impact
Share to Trace Elements in Health

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22792399
DOI: 10.1371/journal.pone.0040717

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 20 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to Paclitaxel in a Cisplatin-Resistant Ovarian Cancer Cell Line Is Mediated by P-GlycoproteinPMID 22792399Read ↗

A highly annotated database of genes associated with platinum resistance in cancerSemantic proximity Read ↗

Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian TumorsSemantic proximity Read ↗

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Semantic proximity Read ↗

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicinSemantic proximity Read ↗

Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper.Semantic proximity Read ↗

Can Cisplatin Therapy Be Improved? Pathways That Can Be TargetedSemantic proximity Read ↗

Molecular profiling of platinum resistant ovarian cancerSemantic proximity Read ↗

Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cellsSemantic proximity Read ↗

Role of copper transporters in platinum resistanceSemantic proximity Read ↗

Mechanisms of multidrug resistance in cancer treatment.Semantic proximity Read ↗

Systems biology of cisplatin resistance: past, present and futureSemantic proximity Read ↗

Altered localisation of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.